iA Global Asset Management Inc. Purchases 766 Shares of Regeneron Pharmaceuticals, Inc. $REGN

iA Global Asset Management Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 21,014 shares of the biopharmaceutical company’s stock after purchasing an additional 766 shares during the quarter. iA Global Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $16,220,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. WPG Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Caitlin John LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $34,000. FNY Investment Advisers LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $38,000. Finally, Torren Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $38,000. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on REGN. Royal Bank Of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $826.59.

Regeneron Pharmaceuticals Stock Down 2.1%

REGN opened at $698.25 on Friday. The stock has a market cap of $73.82 billion, a PE ratio of 17.01, a P/E/G ratio of 1.55 and a beta of 0.30. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The business’s fifty day simple moving average is $744.69 and its 200 day simple moving average is $744.97.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.22 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.